A Randomized, Double-Blind, Placebo-Controlled Study of LY2951742 (Galcanezumab) in Japanese Patients With Episodic Migraine
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 13 Apr 2018
At a glance
- Drugs Galcanezumab (Primary)
- Indications Migraine
- Focus Therapeutic Use
- Sponsors Eli Lilly
- 10 Apr 2018 Planned End Date changed from 1 Mar 2019 to 1 Feb 2019.
- 10 Apr 2018 Planned primary completion date changed from 1 Mar 2019 to 1 Feb 2019.
- 10 Apr 2018 Status changed from recruiting to active, no longer recruiting.